{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Radiopharmaceutical Compound[C1446]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
IOLOPRIDE I-123 (also known as I-123 iodobenzamide), a radioactive drug that can be seen by Single-photon emission computed tomography. This drug binds to the some dopamine receptors and can be used in the neonatal period. It shows the biochemical maturation of D2 receptors and also manifests the deleterious effect of perinatal hypoxic-ischemic events on D2 receptors.
Status:
Possibly Marketed Outside US
Source:
NCT01956409: Phase 4 Interventional Unknown status Breast Cancer Diagnosis
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fluorocholine-F18 is a tracer for positron emission tomography that can be used in oncology for the evaluation of metastatic prostate cancer, hepatocellular carcinoma, and recurrent brain tumor. After crossing the cell membrane by a carrier-mediated mechanism, Fluorocholine-F18 is converted to cytidinediphosphatecholine and incorporated into phosphatidylcholine which is a component of the cell membrane. This process has been found to be upregulated in malignant cells, providing a mechanism for the enhanced accumulation of radiolabelled choline by neoplasms.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(1976)
Source:
BLA017837
(1976)
Source URL:
First approved in 1976
Source:
BLA017837
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1987)
Source:
BLA017881
(1987)
Source URL:
First approved in 1976
Source:
PULMOLITE by JUBILANT DRAXIMAGE
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zirconium (⁸⁹Zr) crefmirlimab berdoxam [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01678417: Phase 2 Interventional Unknown status Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02665065: Phase 3 Interventional Active, not recruiting Acute Myeloid Leukemia
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03867682: Phase 1/Phase 2 Interventional Recruiting Acute Myeloid Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00003478: Phase 1/Phase 2 Interventional Completed Brain and Central Nervous System Tumors
(1997)
Source URL:
Class:
PROTEIN
